ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,721.60
0.00%
S&P ASX All Technology
3,063.30
0.00%
Brent Oil
83.95
0.47%
US Dollar vs AUD
1.51012
-0.68%
Bitcoin
63,206.28
3.30%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. BridgeBio Pharma Inc (BBIO)

  7. BridgeBio Pharma Inc (BBIO) News

BBIO BridgeBio Pharma Inc

28.10
0.40 (1.44%)
After Hours
Last Updated: 08:43:41
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
BridgeBio Pharma Inc BBIO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.40 1.44% 28.10 08:43:41
Open Price Low Price High Price Close Price Previous Close
27.67 27.38 28.755 28.73 27.70
more quote information »

Recent News

Date Time Source Heading
02/5/202421:30GLOBEBridgeBio Pharma Reports First Quarter 2024 Financial..
02/5/202421:00GLOBEBridgeBio launches BridgeBio Oncology Therapeutics (BBOT)..
10/4/202421:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
08/4/202403:15GLOBEBridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR)..
20/3/202422:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
07/3/202409:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07/3/202409:13EDGAR2Form 8-K - Current report
06/3/202415:53GLOBEBridgeBio Pharma Announces Pricing of Public Offering of..
05/3/202409:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/3/202408:17GLOBEBridgeBio Pharma Announces Proposed Public Offering of..
04/3/202423:00EDGAR2Form 8-K - Current report
04/3/202418:30GLOBEBridgeBio Pharma and Bayer Announce European Licensing..
23/2/202408:27EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202423:31EDGAR2Form 8-K - Current report
22/2/202423:30GLOBEBridgeBio Pharma Reports Fourth Quarter and Full Year 2023..
22/2/202408:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202408:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202408:06EDGAR2Form 144 - Report of proposed sale of securities
14/2/202408:05EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
14/2/202408:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202423:34GLOBEBridgeBio Pharma and Kyowa Kirin Announce Partnership with..
06/2/202423:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
05/2/202423:30GLOBEBridgeBio Pharma Announces U.S. Food and Drug Administration..
02/2/202423:00GLOBEBridgeBio Pharma Shares Positive Results of Single-Arm Phase..
30/1/202423:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
19/1/202408:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202423:30EDGAR2Form 8-K - Current report
18/1/202423:00GLOBEBridgeBio Pharma Secures up to $1.25 Billion of Capital from..
17/1/202408:04EDGAR2Form 144 - Report of proposed sale of securities
11/1/202409:15GLOBEBridgeBio Pharma Announces Publication of Positive Results..
10/1/202423:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
09/1/202409:14EDGAR2Form 8-K - Current report
06/1/202408:06EDGAR2Form S-8 - Securities to be offered to employees in employee..
04/1/202408:30GLOBEBridgeBio Pharma to Participate in the J.P. Morgan..
03/1/202423:30GLOBEBridgeBio announces FDA clearance of IND application for..
20/12/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202308:13EDGAR2Form 144 - Report of proposed sale of securities
13/12/202323:30GLOBEBridgeBio Announces First Child Dosed in PROPEL 3, its Phase..
08/12/202323:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
06/12/202300:52DJNBridgeBio Seeks FDA Approval of Acoramidis in Transthyretin..
05/12/202323:44GLOBEBridgeBio Pharma Announces Submission of New Drug..
21/11/202308:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202308:27EDGAR2Form 144 - Report of proposed sale of securities
18/11/202308:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202308:03EDGAR2Form 144 - Report of proposed sale of securities
13/11/202302:30GLOBEBridgeBio Pharma Presents Additional Clinical Outcomes Data..
09/11/202323:30GLOBEBridgeBio Pharma to Present Additional Data from the Phase 3..
08/11/202323:30GLOBEBridgeBio Pharma Reports Inducement Grants under Nasdaq..
03/11/202307:59EDGAR2Form S-3ASR - Automatic shelf registration statement of..
02/11/202322:31EDGAR2Form 8-K - Current report

Your Recent History

NASDAQ
BBIO
BridgeBio Pharma
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved